Comprehensive Evaluation of Cardiac, Endocrine, and Genetic Factors in Young Basketball Athletes
-
By
-
Katerina Gregorova
-
Lukas Plachy
-
Vaclav Chaloupecky
-
Olena Iurchenko
-
Klara Maliska Maratova
-
Aneta Kodytkova
-
Martin Matoulek
-
Jan Lebl
-
Viktor Tomek
-
Zdenek Sumnik
-
Petra Dusatkova
-
Stepanka Pruhova
-
July 20, 2026
Clinical Scorecard: Comprehensive Evaluation of Cardiac, Endocrine, and Genetic Factors in Young Basketball Athletes
At a Glance
| Category | Detail |
|---|
| Condition | Tall stature in young basketball athletes |
| Key Mechanisms | Potential cardiovascular and genetic disorders associated with tall stature |
| Target Population | Adolescent basketball players, median age 17 years |
| Care Setting | Sports medicine evaluation |
Key Highlights
- Echocardiographic abnormalities found in 7% of athletes
- 47% of participants exhibited clinically relevant dysmorphic features
- 1.8% diagnosed with Marfan syndrome due to FBN1 gene variant
- Routine screening may miss cardiovascular conditions
- Height > 2 SD used to categorize tall stature
Guideline-Based Recommendations
Diagnosis
- Consider echocardiography and genetic testing in selected individuals
Management
- Routine laboratory tests and ECG are performed, but echocardiogram is not mandatory
Monitoring & Follow-up
- Ongoing monitoring by sports physicians is recommended
Risks
- Increased risk of sudden cardiac death (SCD) in tall athletes
Patient & Prescribing Data
Youth basketball players with tall stature
No endocrine dysfunctions detected; focus on cardiovascular and genetic evaluations
Clinical Best Practices
- Implement targeted evaluations for athletes with tall stature
- Utilize comprehensive genetic testing to identify hidden health risks
Related Resources & Content
